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Phosphorothioate Backbone Modification Modulates
Macrophage Activation by CpG DNA1
David P. Sester, Shalin Naik, Shannon J. Beasley, David A. Hume, and Katryn J. Stacey2
Macrophages respond to unmethylated CpG motifs present in nonmammalian DNA. Stabilized phosphorothioate-modified oli-
godeoxynucleotides (PS-ODN) containing CpG motifs form the basis of immunotherapeutic agents. In this study, we show that
PS-ODN do not perfectly mimic native DNA in activation of macrophages. CpG-containing PS-ODN were active at 10- to 100-fold
lower concentrations than corresponding phosphodiester ODN in maintenance of cell viability in the absence of CSF-1, in induc-
tion of NO production, and in activation of the IL-12 promoter. These enhancing effects are attributable to both increased stability
and rate of uptake of the PS-ODN. By contrast, PS-ODN were almost inactive in down-modulation of the CSF-1R from primary
macrophages and activation of the HIV-1 LTR. Delayed or poor activation of signaling components may contribute to this, as
PS-ODN were slower and less effective at inducing phosphorylation of the extracellular signal-related kinases 1 and 2. In addition,
at high concentrations, non-CpG PS-ODN specifically inhibited responses to CpG DNA, whereas nonstimulatory phosphodiester
ODN had no such effect. Although nonstimulatory PS-ODN caused some inhibition of ODN uptake, this did not adequately explain
the levels of inhibition of activity. The results demonstrate that the phosphorothioate backbone has both enhancing and inhibitory
effects on macrophage responses to CpG DNA. The Journal of Immunology, 2000, 165: 4165–4173.
S ince the original descriptions of the immunostimulatoryactions of unmethylated CpG motifs in nonmammalianDNA, there has been a widespread recognition of the im-
plications for gene and antisense therapy, DNA vaccination, and
immunotherapy (reviewed in Refs. 1–3). Whereas in DNA vac-
cines the active moieties that contribute adjuvant activity are na-
tive dsDNA molecules, most other applications of CpG DNA have
used nuclease-resistant phosphorothioate-modified oligodeoxynu-
cleotides (PS-ODN).3 PS-ODN have sulfur substituted for one of
the nonbridging oxygens in the phosphodiester backbone. Phos-
phorothioate-stabilized CpG DNA is an effective adjuvant in vac-
cinations (4–7) as well as having potential in immunotherapy of
inflammatory and allergic disease (8–10).
Phosphodiester oligodeoxynucleotides (PO-ODN) containing
CpG motifs mimic the direct effects of native bacterial DNA in
vitro, including activation of macrophages, dendritic cells, and B
lymphocytes. The short t1/2 of PO-ODN in vivo (11) precludes
their use in therapy. It is relevant to ask whether the more stable
PS-ODN mimic all of the actions of native phosphodiester CpG
DNA. Recognition of the differences, and their molecular basis,
may direct the identification of more effective mimetics of bacte-
rial DNA for clinical application. There have been few compara-
tive studies of CpG PS- and PO-ODN. Published observations vary
depending on the cell system used and the effector function mea-
sured. A CpG PS-ODN was effective at promoting survival of
human dendritic cell precursors from peripheral blood at lower
concentrations than a CpG PO-ODN (12), but the length and se-
quence of the respective PS-ODN and PO-ODN were not identical.
Studies by Boggs et al. (13) using sequence identical PS-ODN and
PO-ODN demonstrated that for NK cell activation PO-ODN were
less active than corresponding PS-ODN, but the situation was re-
versed when a transfection reagent, lipofectin, was added. Several
studies indicate that PS-ODN are more potent than corresponding
PO-ODN at inducing B cell proliferation (14–17). Studies on B
cell proliferation are complicated by the fact that human and
mouse B cells can respond to PS-ODN in a CpG-independent man-
ner (18, 19). In addition, if using thymidine uptake as a measure of
proliferation, PO-ODN degradation can dilute the radioactive thy-
midine pool (20). PS-ODN have also been found to be more potent
in induction of spleen cell IL-12 and CD69 expression (15).
CpG DNA mimics many of the actions of bacterial LPS on
murine macrophages, including activation of NF-kB-dependent
transcription and release of cytokines such as TNF-a, IL-6, and
IL-12 (21–25). In this study, we use a range of assays of macro-
phage activation to compare the actions of PS-ODN and PO-ODN
of identical sequence. The results show that the two types of ODN
have distinct activities and PS-ODN do not function merely as a
more stable version of active PO-ODN.
Materials and Methods
Cells and reagents
The murine macrophage-like cell line, RAW264, was obtained from
the American Type Culture Collection (Manassas, VA). Bone marrow-
derived macrophages (BMM) were obtained by cultivation of femoral bone
marrow cells for 1 wk on bacteriological petri dishes in recombinant
human macrophage CSF (CSF-1) (a gift from Chiron, Emeryville, CA),
as described previously (26). The medium in all experiments was RPMI
1640 plus 10% heat-inactivated FBS with 20 U/ml penicillin and 20 mg/ml
streptomycin. Serum was screened for low LPS contamination using
RAW264a4 cells. RAW264a4 is a stable transfectant of RAW264 with an
integrated HIV-1 LTR-luciferase reporter gene that is activated by low
concentrations of LPS, or CpG DNA (21, 27).
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PO-ODN and PS-ODN were purchased from Geneworks (Adelaide,
Australia) or Oligos Etc. (Wilsonville, OR). AO-1, a PO-ODN, has the
sequence 59-GCTCATGACGTTCCTGATGCTG-39, which is similar to
the oligo 1668 of Yi et al. (28), with the addition of terminal G residues.
NAO-1 is the same sequence with the core CG (underlined) reversed to
GC. AOS-1 and NAOS-1 are the corresponding PS-ODN. AAC-22 (29) is
slightly less active than AO-1 and has the sequence ACCGATAACGTT-
GCCGGTGACG. SAAC-22 is the phosphorothioate version of AAC-22.
Results obtained with AO-1 and AAC-22 or their corresponding phospho-
rothioate versions were similar and they could be used interchangeably in
this work. For uptake experiments, AO-1 and AOS-1 were purchased with
a Cy3 fluorophore attached at the 59 end. LPS from Salmonella minnesota
Re595 was purchased from Sigma (St. Louis, MO) and was dissolved as a
10 mg/ml stock solution in 0.1% triethylamine and sonicated. Fluorescein-
labeled anionic dextran, 10,000 m.w., was purchased from Molecular
Probes (Eugene, OR).
Luciferase assays
For the HIV-1 LTR assay, 2.5 3 105 RAW264a4 cells were placed in 1 ml
of medium in a 24-well plate overnight. After reduction of the total volume
to 0.5 ml, cells were incubated with stimuli for 2 h, unless stated otherwise.
Cells were harvested and assayed for luciferase activity, as described (21,
27), except that the assays were conducted using a Trilux plate luminom-
eter and reagents provided by Packard Instruments (Meriden, CT). For
analysis of IL-12 promoter activity, the murine IL-12 p40 promoter, as
described by Cowdery et al. (25), was amplified by PCR and subcloned
into the pGL2 luciferase vector by Dr. E. Gold (University of Washington
School of Medicine, Seattle, WA) RAW264 cells were transfected with 10
mg of pGL2-IL12p and 2 mg of the selectable plasmid pNeo/Tak (30), as
described (31), and subjected to selection in 200 mg/ml G418 for 2 wk.
Approximately 200 colonies appeared on the dishes. These were harvested
and pooled, and grown for a further week in G418 before assay. Inducible
luciferase activity has been maintained thereafter for several months in
culture. For the IL-12 promoter assay, 105 cells were incubated in 1 ml
medium overnight, followed by addition of ODN for 6 h, then lysis and
assay as above.
Nitrite assay
The assay of nitrite using the Griess reagent was used as an indicator of NO
production by both BMM and RAW264, as described previously (23).
Briefly, 4 3 104 RAW264 or 105 BMM (with 104 U/ml CSF-1) were plated
in 96-well plates in 200 ml supplemented RPMI and cultured overnight.
Cells were then pretreated with 20 U/ml murine rIFN-g for 2 h (R&D
Systems, Minneapolis, MI), followed by addition of the triggering stimu-
lus. After 24 h, supernatants were removed and assayed for nitrite.
Cellular viability assay
The reduction of the dye MTT (Sigma) was used to measure relative num-
ber of viable cells. BMM were harvested and plated in CSF-1-free medium
for 18 h (5 3 104 cells/well in 200 ml in a 96-well plate). The desired
additions were made, and the cells were incubated for an additional 48 h
before assessment of MTT reduction, as described previously (32).
Down-modulation of surface CSF-1R
BMM were starved of CSF-1 overnight, then incubated with the desired
treatments on bacteriological petri dishes, before being immunostained for
surface expression of CSF-1R using the specific mAb AFS98, as described
previously (32).
Phosphorylation of ERK-1/2
Cell extracts and Western blotting for the determination of the phosphor-
ylation state of the extracellular signal-regulated kinases 1 and 2 (ERK-1/2)
were conducted as described previously (32).
Intracellular TNF-a assays
For the plate assay, RAW264 cells were plated at 105 cells/well in 96-well
plates and incubated overnight. To increase cellular retention of TNF-a,
brefeldin A (10 mg/ml) was added 15 min before incubation with ODN for
2 h. Cells were washed once in ice-cold PBS and fixed with 20% acetone,
0.02% BSA in PBS for 2 h at 4°C. Cells were washed three times with
PBS, blocked for 1 h with 1% BSA in PBS, and then incubated for 1 h with
1/4000 dilution of rabbit anti-mouse TNF-a Ab (Genzyme, Cambridge,
MA) in PBS/1% BSA. Cells were washed three times with 0.2% Tween 20
in PBS, for a total of 20 min, then incubated for 1 h with 1/1000 dilution
of secondary Ab (anti-rabbit HRP conjugate; New England Biolabs, Bev-
erly, MA) in PBS/1% BSA. Secondary Ab was removed and cells were
incubated for 30 min in 5% goat serum in PBS/1% BSA. Cells were
washed three times with 0.2% Tween 20 in PBS, for a total of 20 min, and
then once in PBS. Color development with 2,29-azinobis(3-ethylbenzthia-
zoline-6-sulfonic acid) (ABTS) reagent (560 mg/ml ABTS (Sigma),
0.008% H2O2, 50 mM citric acid, 0.1 M Na2HPO4, pH 4.2) was measured
at 415 nm.
For FACS analysis, RAW264 cells plated in 1 ml of medium were
treated with 5 mg/ml brefeldin A together with ODN for 4 h. Cells were
harvested and stained for intracellular TNF-a, as described by Underhill et
al. (30).
ODN and dextran uptake
RAW264 cells were plated overnight at 250,000/well in 1 ml of medium in
24-well plates, and reduced to 0.25 ml before addition of ODN. Cy3-
labeled ODN were added for the indicated times before removal of super-
natant and addition of ice-cold PBA (PBS/0.1% BSA/0.1% sodium azide).
Cells were harvested, and incubated on ice for 10 min with 25 mg/ml
dextran sulfate in PBA to remove surface-bound ODN. Cells were then
washed twice in 5–10 ml PBA and analyzed by flow cytometry on a FAC-
Scalibur (Becton Dickinson, San Jose, CA) for internalized ODN. Control
samples in which cells were incubated with ODN on ice to allow cell
surface binding but not internalization showed that the procedure did ef-
fectively strip off surface-bound ODN. Results were corrected for a slight
difference in the degree of fluorochrome labeling of the two ODN, AO-1
and AOS-1. For fluorescein-labeled dextran uptake, cells were processed as
for ODN uptake experiments, except incubation with dextran sulfate was
omitted.
Results
PS-ODN are more potent than PO-ODN in induction of NO,
promotion of cell survival, and activation of the IL-12 promoter
Macrophages primed with IFN-g respond to exposure to CpG
DNA with expression of inducible NO synthetase mRNA and in-
creased NO production (21, 23). PO-ODN and PS-ODN of the
same sequence (AO-1 and AOS-1) were compared for their ability
to induce NO production in IFN-primed BMM and RAW264 cells
in Fig. 1, A and B, respectively. The dose-response curves for the
primary cells and the cell line are almost indistinguishable. Both
ODN were active, but AOS-1 was much more potent with re-
sponses detectable at ;100-fold lower concentration than for
AO-1. The PS-ODN AOS-1 always gave a lower maximal activity
than AO-1. High AOS-1 concentrations caused NO production to
decline from the maximum. A second pair of PO- and PS-ODN,
AAC-22 and SAAC-22, gave a similar difference in potency, and
inhibition of response at high PS-ODN concentration (result not
shown). CpG specificity was preserved for the response to AOS-1,
although low levels of NO production were observed occasionally
with the PS-ODN NAOS-1 (see Fig. 11), which differs only in
having a reversal of the CpG motif to GpC.
Because the induction of NO production by CpG DNA depends
upon IFN-g priming, we considered the possibility that IFN sen-
sitized specifically to PS-ODN. We have shown elsewhere that
CpG DNA can prevent apoptosis that occurs in BMM deprived of
the macrophage growth and survival factor, CSF-1 (32). Fig. 2
compares the dose-response curves for the antiapoptotic activity of
AO-1 and AOS-1. Assessment of viable cell number was based
upon reduction of the dye MTT by the mitochondrial enzyme suc-
cinate dehydrogenase. Because this assay is sensitive to factors
that alter mitochondrial respiration, we have previously validated
it for this use by showing a good correlation between MTT reduc-
tion and direct cell count (32). AO-1 and AOS-1 both maintained
cell viability in the absence of CSF-1, whereas the corresponding
GpC transversions lacked activity. In comparative dose-response
curves, AOS-1 was ;30-fold more active than AO-1 (Fig. 2). The
dose-response curves for AOS-1 and AO-1 were similar in the cell
viability and NO assays, suggesting that IFN-g does not sensitize
preferentially to phosphorothioate CpG DNA. As both the NO
4166 PHOSPHOROTHIOATE EFFECT ON CpG DNA ACTIVITY
 by guest on January 23, 2014
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
assay and the antiapoptotic assay involve incubation for extended
periods in culture, the first explanation considered for the higher
activity of PS-ODN was their stability relative to PO-ODN. We
therefore examined several shorter term assays, in which a smaller
difference in activity of PS- and PO-ODN might be expected.
Stimulation of an IL-12 promoter-reporter construct in RAW264
cells for 6 h gave a similar threshold for response to PO-ODN as
the previous assays (Fig. 3). Again, the PS-ODN was active at
much lower concentrations and had a lower maximal activity than
the PO-ODN.
PS-ODN are less active than PO-ODN in activation of the HIV-
1 LTR and down-modulation of cell surface CSF-1R
In previous work, we have measured NF-kB-dependent transcrip-
tion in macrophages after 2-h exposure to CpG DNA, using a
RAW264 cell line with an integrated HIV-1 LTR luciferase re-
porter construct (21). Using this assay (Fig. 4A), the PO-ODN
AO-1 gave a similar dose-response curve to the longer term NO
and antiapoptotic assays (Figs. 1 and 2). By contrast, the corre-
sponding PS-ODN, AOS-1 was almost inactive. The same pattern
was observed with the PO-ODN AAC-22 and its corresponding
PS-ODN SAAC-22 (Fig. 4B). Both PS-ODN caused a minimal
activation of the HIV-1 LTR at low concentration, but had little
additional impact with increasing concentration.
BMM treated with either bacterial DNA, CpG PO-ODN, or LPS
rapidly down-modulate cell surface expression of the CSF-1R, a
response that occurs in an all-or-nothing manner at the single cell
level (32). Dose-response analysis of CSF-1R down-modulation
was conducted with AOS-1 and AO-1 (Fig. 5, A and B). Fig. 5A
shows the representative flow-cytometric profiles. Increasing
AO-1 concentration increased the proportion of cells with com-
pletely down-modulated CSF-1R (falling within the M1 gate).
Similar to the observations made with activation of the HIV-1
LTR, PS-ODN were much less active than their PO-ODN coun-
terparts. After a 1-h incubation with ODN at a concentration of 3
mM, AOS-1 increased the percentage of cells with receptor down-
modulation from 12% to 25%, whereas with AO-1 95% of cells
fully down-modulated their CSF-1R. The same trend was observed
in a comparison of SAAC-22 and AAC-22 (Fig. 5C).
PS-ODN give delayed and reduced phosphorylation of ERK-1/2
Maintenance of cell viability in CSF-1-starved BMMs is associ-
ated with the ability of both LPS and CpG DNA to activate the
MAP kinases, ERK-1/2 (32). LPS causes rapid activation of the
MAP/ERK kinase-1, which in turn phosphorylates ERK-1/2. A
stimulatory ODN such as AO-1 acts more slowly than LPS, per-
haps reflecting the time required for ODN internalization (unpub-
lished observation). Fig. 6A compares the time course of activation
of ERK-1/2 in BMM by AO-1 and AOS-1. AO-1 caused maximal
phosphorylation of ERK-1/2 by 20 min, followed by a decline to
an elevated steady state after 40 min. By contrast, AOS-1 showed
no induction of ERK-1/2 phosphorylation at 20 min, and reached
a peak at 1 h that was less than the maximal phosphorylation
observed with AO-1. Both ODN treatments in Fig. 6A were 3 mM.
Because AOS-1 seems to have some self-inhibitory action at this
concentration (Figs. 1 and 2), we checked whether lower concen-
trations could induce earlier phosphorylation of ERK-1/2. Fig. 6B
shows that concentrations of AOS-1 between 0.1 and 1 mM were
also unable to stimulate ERK-1/2 phosphorylation at 20 min. We
found a similar delay in ERK-1/2 phosphorylation in response to
AOS-1 in RAW264 cells (result not shown).
FIGURE 1. PS-ODN are more potent in induction of NO production
than sequence identical PO-ODN. BMM (A) or RAW264 cells (B) were
primed for 2 h with 20 U/ml IFN-g, then incubated for an additional 24 h
with the indicated concentration of PS-ODN (AOS-1, NAOS-1) or PO-
ODN (AO-1, NAO-1). Nitrite was measured in the supernatant. Data are
the average and SD of triplicates. The experiment is representative of three.
FIGURE 2. PS-ODN are more active than PO-ODN in maintenance of
viability of BMM. BMM were starved of CSF-1 for 18 h, then treated with
the indicated concentrations of PS-ODN (AOS-1, NAOS-1) or PO-ODN
(AO-1, NAO-1) for an additional 48 h. Cleavage of the dye MTT to form
an insoluble formazan product was measured as an indication of the num-
ber of viable cells. Results are the mean and SD of triplicates. The result
is representative of three experiments.
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PS-ODN are taken up more rapidly than PO-ODN
Delayed ERK-1/2 phosphorylation, poor activation of the HIV-1
LTR at 2 h, and little down-modulation of the CSF-1R at 1 h by
PS-ODN suggested a slower cellular activation by PS-ODN than
PO-ODN. Cellular activation by CpG DNA apparently requires
DNA uptake (20). Ineffective activation by PS-ODN in some
short-term assays might potentially be explained by slower uptake
into the cell. Previous studies have shown PO-ODN to be more
rapidly taken up than PS-ODN in a colorectal adenocarcinoma cell
line (33), but faster uptake of PS-ODN in renal epithelial cells (34)
and B cells (35). To check whether poor responses were due to
slower uptake of PS-ODN, we measured cellular accumulation of
Cy3-labeled PS- and PO-ODN by flow cytometry. Cy3 is not pH
sensitive between pH 5 and 7.5 and is therefore unaffected by
endosomal acidification. Fig. 7 shows that PS-ODN actually ac-
cumulated much more rapidly than PO-ODN in RAW264 cells.
The slower cellular accumulation of PO-ODN seen in this study
was not due to its extracellular degradation, because the differen-
tial uptake was maintained in cells freshly plated in serum-free
medium (result not shown). Given that the difference in rates of
uptake was apparent after only 5 min, it is also not likely to be due
to intracellular degradation of PO-ODN and exocytosis of the Cy3
label. Thus, slow uptake of PS-ODN is not responsible for its poor
activity in some assays. The possibility remains that PS-ODN take
longer to reach the site of detection of CpG DNA within the cell.
PS-ODN efficiently induce TNF-a
Although PS-ODN did not efficiently activate macrophages in two
other assays performed after 1 and 2 h of stimulation (Figs. 4 and
5), it did induce TNF-a protein in a 2-h incubation (Fig. 8A). The
response to low concentrations of PS-ODN was less sensitive than
in the longer term NO and apoptotic assays, with first responses
seen at 0.1 mM rather than 0.03 mM. Nevertheless, any delay in
signaling in response to PS-ODN is insufficient to prevent induc-
tion of TNF-a at 2 h. Analysis at the single cell level using flow
cytometry showed that AOS-1 induced lower levels of TNF-a in
individual cells than AO-1 (Fig. 8, B and C). In addition, although
all cells responded to 3 mM AO-1, a population of cells failed to
be stimulated by the PS-ODN AOS-1. The lower peak response,
and decline in activity at high PS-ODN concentration seen in this
study (Fig. 8A) and in other assays (Figs. 1, 2, and 3) suggested
that PS-ODN have an inhibitory action at high concentration.
Given this, we investigated whether this inhibition was an inherent
property of PS-ODN and whether non-CpG PS-ODN can block the
CpG response.
Blockade of CpG DNA responses by non-CpG PS-ODN
Ha¨cker et al. (36) have presented evidence that non-CpG PS-ODN
can block the response to CpG PS-ODN. Whether the same applies
for PO-ODN has not previously been addressed. Preincubation or
cotreatment with an equimolar concentration (2 mM) of the inac-
tive PO-ODN NAO-1 had no significant effect on activation of
HIV-1 LTR-dependent luciferase activity in RAW264 cells in-
duced by AO-1. Both pre- and cotreatment with an equimolar con-
centration of the equivalent PS-ODN NAOS-1 substantially dimin-
ished activation by AO-1 (Fig. 9A). Even a 6-fold molar excess of
the non-CpG PO-ODN NAO-1 had no effect on the response to
AO-1 at a concentration that was near saturating in biological CpG
activity (Fig. 9B). The effect of non-CpG PS-ODN was specific in
that it reduced CpG DNA-mediated activation of the HIV-1 LTR,
but not activation mediated by LPS (Fig. 9A). Because even the
CpG-containing PS-ODN were inactive in the HIV-1 LTR assay,
we examined whether they might also be inhibitory. Indeed,
SAAC-22 was also able to prevent activation by AO-1 and
AAC-22 (not shown). These findings indicate that PS-ODN have
a dominant repressive effect on the ability of CpG DNA, but not
LPS to activate in this assay.
FIGURE 3. PS-ODN are more active than PO-ODN in activation of the
IL-12p40 promoter. RAW264 cells stably transfected with a mouse IL-12
promoter-luciferase reporter were incubated for 6 h with the indicated con-
centrations of ODN before harvesting for determination of luciferase ac-
tivity. Results are the average of duplicates, and the experiment is repre-
sentative of three.
FIGURE 4. CpG PS-ODN do not activate the HIV-1 LTR. RAW264a4
cells, with an integrated HIV-1 LTR-luciferase reporter gene, were incu-
bated for 2 h with the ODN at the indicated concentrations before being
harvested for determination of luciferase activity. The activity observed in
unstimulated cells is arbitrarily given a value of 1. Results are the average
and SD of triplicates. The experiments are representative of at least three.
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The time course of PS-ODN-specific blockade of HIV-1 LTR
activation by AO-1 was investigated in Fig. 10. There was no
requirement for pretreatment; in fact, the extent of inhibition was
greatest when PS-ODN were coadministered, whereas there was
little effect where it was added only 15 min after treatment with
AO-1. The lack of inhibition following delayed addition is
FIGURE 5. CpG PS-ODN fail to down-modulate the CSF-1R from the cell surface of BMM. BMM were starved of CSF-1 overnight, then incubated
with the indicated concentrations of ODN for 1 h and immunostained for surface expression of CSF-1R. A, Representative FACS profiles from one
experiment. B, Analysis of the proportion of cells showing down-modulated CSF-1R (the M1 fraction shown in A) in response to the indicated ODN concentrations.
C, Analysis of the proportion of cells showing down-modulated CSF-1R in a separate experiment with PO-ODN AAC-22 and PS-ODN SAAC-22.
4169The Journal of Immunology
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consistent with the pattern of activation of ERK-1/2 (see Fig. 6),
which is already maximal after 20 min. High dose inhibition ob-
served in the dose-response curve for PS-ODN activation of NO
production could also reflect a compromise between stimulation by
the CpG motif, and inhibition by the backbone. This possibility
was investigated by preincubating cells with non-CpG ODN. As
seen in the HIV-1 LTR assay, nonstimulatory PS-ODN blocked
the response to AO-1, whereas minimal inhibition of the LPS re-
sponse was observed (Fig. 11). Responses to the PS-ODN AOS-1
and SAAC-22 were also inhibited by non-CpG PS-ODN (result
not shown). By contrast, there was no inhibition by the corre-
sponding non-CpG PO-ODN (NAO-1) (Fig. 11) even at concen-
trations of 10 mM (result not shown).
Ha¨cker et al. (36) have shown inhibition of TNF-a, IL-6, and
IL-12 production in a macrophage cell line by non-CpG PS-ODN.
They also showed by fluorescence microscopy that at a concen-
tration of 3 mM, non-CpG PS-ODN blocked the uptake of an ac-
tive PS-ODN at 1 mM. We examined the effect of pretreatment
with PS- or PO-ODN on the uptake of Cy3-labeled ODN (Fig. 12).
The PO-ODN NAO-1 at 9 mM had minimal effect on ODN uptake.
Increasing concentrations of NAOS-1 reduced the uptake of Cy3-
AOS-1. However, although 9 mM NAOS-1 reduced the uptake of
the PO-ODN Cy3-AO-1 by 50%, at lower concentrations NAOS-1
had no effect or was even stimulatory. Thus, inhibition of uptake
does not account for the inhibition of activity of AO-1 seen with
NAOS-1 between 1 and 3 mM (Figs. 9 and 11). NAOS-1 did not
inhibit uptake of fluorescein-labeled dextran (Fig. 12), indicating
that PS-ODN had no effect on fluid-phase uptake in macrophages.
Discussion
Interest in studying the responses to CpG-containing DNA arises
from several distinct biological applications. In gene therapy,
DNA vaccination, and the possible roles of CpG DNA sequences
in host-pathogen interaction, the active molecules are native phos-
phodiester DNAs. Applications of CpG DNA in immunotherapy
and antisense therapy are based on phosphorothioate-modified
backbones. In this study, we have shown that PS-ODN have quite
distinct activities from PO-ODN in the activation of macrophages.
The phosphorothioate modification of ODN is necessary for ef-
fective immunomodulatory effects to be seen in vivo. The general
assumption is that this is due to the increase in stability of the
ODN, as PO-ODN are rapidly degraded in vivo (11). PS-ODN also
have significantly greater stability in vitro. Matsukura et al. (37)
found the t1/2 of PO-ODN in medium with 15% FCS to be 17 h,
while PS-ODN showed no degradation after 7 days. Another report
found PO-ODN within spleen cells was partially degraded after
4-h incubation, although PS-ODN was intact (35). Even after 72-h
incubation, PS-ODN was 90% intact in cells and culture medium
(38). If CpG PS-ODN behaved just like PO-ODN but with greater
stability, then we would expect that long-term assays would show
the greatest disparity in activity between the two types of ODN.
There would be a fairly constant response to PS-ODN in different
assays and a declining relative potency of PO-ODN as the time of
incubation increased. This is not what we have observed. Regard-
less of the length of incubation, the dose response for PO-ODN in
a range of assays was fairly similar, with activity evident at con-
centrations above 0.3–1 mM (Figs. 1–5 and 8). The effects of the
phosphorothioate modification varied widely between assays. Re-
sponses to PS-ODN were evident at 10–100-fold lower concen-
trations than PO-ODN for induction of NO, activation of the IL-12
promoter, and prevention of cell death (Figs. 1–3). The much
greater potency of PS-ODN in these assays, and in in vivo immu-
nomodulation is likely to be due not only to greater stability, but
also to much more efficient uptake of PS-ODN (Fig. 7). However,
CpG PS-ODN were much less potent than PO-ODN in down-
modulation of surface expression of the CSF-1R, almost inactive
in activation of the HIV-1 LTR, and gave delayed and reduced
ERK-1/2 phosphorylation (Figs. 4–6).
The poor responses to PS-ODN seen in some of the shorter
assays were not due to slow uptake of PS-ODN. The possibility
remained that PS-ODN is slower in getting to the site of recogni-
tion of foreign DNA, which remains uncharacterized. Endosomal
release could be a rate-limiting step for responses to CpG DNA.
The effective response to PS-ODN in induction of TNF-a protein
by 2 h (Fig. 8A) suggests that this is not the major issue. In addi-
tion, extension of the HIV-1 LTR assay to 6 h failed to give effi-
cient activation by PS-ODN, and treatment of CSF-1-deprived
BMM for 12 h with PS-ODN resulted in only 50% of cells down-
modulating surface expression of the CSF-1R (results not shown).
Thus, there seems to be a qualitatively different response to the
PS-ODN, rather than merely a delayed response. A remaining pos-
sibility for poor activation in some assays is that PS-ODN give a
selective inhibition or lack of activation of certain signaling path-
ways. Coordinated activation of signaling pathways may be im-
portant in some responses, and a delay in activation of pathways
FIGURE 6. PS-ODN induce phosphorylation of ERK-1/2 more slowly
than PO-ODN. BMM were starved of CSF-1 overnight, then incubated for
the indicated times with AO-1 or AOS-1 before lysis and Western blotting
to detect ERK-1/2 phosphorylation. A representative experiment is shown.
A, Cells were treated with 3 mM AO-1 or AOS-1 for various times. B, Cells
were treated with 0.1, 0.3, or 1 mM AOS-1, or 5 mM AO-1 for 20 min.
FIGURE 7. PS-ODN are taken up more rapidly than PO-ODN.
RAW264 cells were incubated with 0.3 or 3 mM Cy3-labeled AOS-1 or
AO-1 for various times. ODN uptake as measured by cellular fluorescence
was determined by flow-cytometric analysis.
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such as the ERK MAP kinases (Fig. 6A) may prevent responses. In
addition, a lowered level of activation of signaling pathways, as
observed for ERK-1/2 with PS-ODN, may stimulate some re-
sponses and not others, if the responses have different thresholds
for activation. A comparison of PS- and PO-ODN activation of
other pathways such as NF-kB, JNK, and p38 will be informative.
Others have reported that CpG PS-ODN can induce NF-kB nu-
clear translocation in RAW264 cells (25). Thus, the failure of PS-
ODN to stimulate the HIV-1 LTR (Fig. 4) suggests that PS-ODN
may poorly activate some of the other transcription factors re-
quired, such as Ets, Sp-1, or PU.1 (39, 40).
Another way in which the two types of ODN vary is the se-
quence-independent inhibitory activity of PS-ODN seen at high
concentrations. Non-CpG PS-ODN at concentrations of 1 mM and
above inhibited responses to both CpG PO-ODN (Figs. 9 and 11)
and PS-ODN (result not shown). This concentration coincides with
the threshold above which CpG PS-ODN exhibit a self-inhibitory
activity (Figs. 1 and 2). Inhibition of responses to PS-ODN at high
concentrations has been observed previously (17). The inhibition
seen in this study was not due to an intrinsic toxicity of high
concentrations of phosphorothioate, as LPS reponses were not
greatly inhibited (Figs. 9 and 11). A previous study has suggested
that non-CpG PS-ODN may inhibit CpG responses by blocking
ODN uptake (36). We found some inhibition of uptake of labeled
ODN after treatment with non-CpG PS-ODN, which was not seen
with high concentrations of non-CpG PO-ODN (Fig. 12). The de-
gree of inhibition of uptake was not sufficient to account for the
inhibition of CpG activity. Thus, we propose that PS-ODN have
two inhibitory activities at high concentration, one that reduces the
uptake of ODN, and another uncharacterized activity accounting
for the self-inhibition seen at higher concentrations with CpG
PS-ODN.
Non-CpG PS-ODN inhibited the uptake of labeled CpG PS-
ODN in a dose-dependent manner, but was less effective at inhib-
iting the uptake of labeled PO-ODN (Fig. 12). This, together with
the much poorer uptake of PO-ODN, suggests a difference in the
mechanism of uptake between the two types of ODN. In K562
human leukemia cells, PS-ODN uptake was primarily receptor me-
diated at concentrations below 1 mM, with fluid-phase uptake be-
coming important at higher concentrations (41). A number of stud-
ies have looked for DNA receptors on the cell surface, but the
mechanism of ODN uptake remains to be established (20, 42). The
integrin MAC-1 (CD18/CD11b) has been implicated as a specific
receptor for ODN in neutrophils (43). We found no evidence to
support this function in murine macrophages, in which ODN treat-
ment did not alter the level of MAC-1 Ag on the cell surface (32).
In addition, cells from mice deficient in MAC-1 have normal ODN
uptake (20).
FIGURE 8. PS- and PO-ODN induce TNF-a. A, Intracellular TNF-a
was measured in RAW264 cells by a plate assay. Cells were incubated with
various concentrations of ODN for 2 h. Results show the average and SD
of triplicate estimations, and are representative of three experiments. B,
Intracellular TNF-a was measured by flow-cytometric analysis. Cells were
incubated with AO-1 at 0, 0.075, 0.15, 0.75, 1.5, and 3 mM for 4 h. Un-
stimulated cells are shown as a dotted line. Increasing concentrations of
ODN are shown, in order, by thin solid line, dashed line, dash-dot, dash-
dot-dot, with the highest concentration a thick solid line. C, Intracellular
TNF-a measured as per B, using the PS-ODN, AOS-1.
FIGURE 9. PS-ODN inhibit activation of the HIV-1 LTR by CpG
DNA. RAW264a4 cells, with integrated HIV-1 LTR-luciferase reporter
gene, were treated with AO-1 or LPS for 2 h before harvesting and deter-
mination of luciferase. Unstimulated luciferase activity is given an arbi-
trary value of 1. A, Cells were incubated with 2 mM AO-1 or 10 ng/ml LPS
for 2 h. They were either pretreated for 2 h, or cotreated with 2 mM non-
stimulatory PO-ODN (NAO-1) or PS-ODN (NAOS-1). B, Cells were in-
cubated with AO-1 at 5 mM, which gives a near maximal response, with or
without 6-fold excess (30 mM) NAO-1. Data shown are the mean and SD
of triplicates.
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In preliminary binding studies with murine macrophages, we
found that PO-ODN had much lower cell surface binding than
PS-ODN (result not show). This has also been found using spleen
cells (35). Because PO-ODN binding to spleen cells is efficiently
competed for by PS-ODN (35), it is unlikely that they are binding
completely different classes of receptor. The differences in rate of
uptake, surface binding, and inhibition of uptake are consistent
with PS-ODN binding and uptake by a high affinity receptor, and
much poorer receptor-mediated uptake of PO-ODN. With low re-
ceptor-mediated uptake, the contribution of fluid-phase uptake of
PO-ODN would become relatively more important, explaining the
poor inhibition of PO-ODN uptake by PS-ODN (Fig. 12). The
absence of an effect of PS-ODN on uptake of labeled dextran in-
dicates that fluid-phase uptake is not inhibited by PS-ODN (Fig.
12). Because receptor-mediated uptake is inherently saturable, the
inhibition of labeled CpG PS-ODN uptake by non-CpG PS-ODN
is likely to be due to competition for receptor binding. Lack of
inhibition by high concentrations of PO-ODN is explained by its
lower affinity for the receptor.
In addition to the inhibitory activities we have observed for
PS-ODN, sequence-independent activation has been documented.
In vivo administration of PS-ODN caused splenomegaly and B cell
proliferation, which was enhanced by the presence of CpG motifs
(18). Sequence-independent activation of human B cells (19) and
enhancement of LPS-induced TNF-a production (44) are thought
to be mediated by PS-ODN interaction with cell surface molecules.
Activation of Sp1 transcription factor has also been observed (45).
Some of these effects may be explained by the enhanced affinity of
PS-ODN for binding to a wide variety of proteins (46, 47). For
example, PS-ODN binding inhibits isoforms of protein kinase C
(48), and can interfere with binding of growth factors to their re-
ceptors (49). Such interactions with signaling molecules could be
responsible for the lack of activation by PS-ODN of some mac-
rophage responses to CpG DNA, as well as the inhibitory effects
we have observed at high concentration. Another effect of the
phosphorothioate modification may be to constrain the three-di-
mensional structure of the ODN and affect its interaction with the
putative CpG receptor. Whether this could have different effects on
different responses, as we have observed in this study, remains to
be established. The poor activity of PS-ODN in eliciting some
responses could be somewhat sequence dependent. Krieg et al. (17,
20) have suggested that the sequence requirements for activity are
more stringent with PS-ODN than with PO-ODN, and another
group has shown a sequence-dependent lack of activity of PS-
ODN in induction of TNF-a (50). Thus, the change in ODN struc-
ture introduced by the phosphorothioate modification seems to
have a greater effect on the immunostimulatory ability of some
sequences than others.
In summary, we have demonstrated that the phosphorothioate
backbone modifies the response to activating CpG sequences in a
number of ways. The phosphorothioate modification that makes
ODN resistant to nuclease attack also greatly enhanced their up-
take into murine macrophages. The increased stability and uptake
are likely to be responsible for the higher potency of PS-ODN in
some assays. However, the PS-ODN failed to efficiently stimulate
some responses. Delayed or poor activation of signaling compo-
nents, such as the ERK MAP kinases, may contribute to this effect.
In addition, PS-ODN have a CpG-selective inhibitory action at
FIGURE 12. High concentrations of PS-ODN reduce labeled ODN up-
take. RAW264 cells were incubated with 0.25 mg/ml fluorescein-labeled
dextran (M), 1 mM Cy3-labeled AOS-1 (p), or 1 mM Cy3-labeled AO-1
(f) for 40 min. They were pretreated for 30 min with the indicated con-
centrations of NAO-1 or NAOS-1. ODN uptake was measured by FACS
analysis. Results are representative of three experiments and show the
mean of duplicates. Error bars show the values of the duplicates. Results
for ODN uptake are shown relative to the control Cy3-AOS sample. Dex-
tran results were normalized to the control sample.
FIGURE 10. Inhibition of CpG DNA response by PS-ODN does not
require preincubation. RAW264a4 cells, with integrated HIV-1 LTR-lu-
ciferase reporter gene, were treated with 2 mM AO-1 for 2 h before har-
vesting for measurement of luciferase activity. The non-CpG PS-ODN
NAOS-1 was added at equimolar concentration at the times indicated rel-
ative to the addition of AO-1. Results are the average and SD of triplicates.
FIGURE 11. PS-ODN prevent activation of NO production induced by
CpG DNA. RAW264 cells were primed with 20 U/ml IFN-g for 2 h, then
treated for 24 h with 1 mM AO-1 or 5 ng/ml LPS, as indicated. Non-CpG
PO-ODN NAO-1, or PS-ODN NAOS-1 were added at the concentrations
shown, either alone, or 30 min before LPS or AO-1. Results are the mean
and SD of triplicates, and are representative of at least three experiments.
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high concentrations that is only partially accounted for by inhibi-
tion of ODN uptake. Thus, PS-ODN do not perfectly mimic a
biological response to natural CpG DNA. Whether this is an ad-
vantage or disadvantage in therapeutic applications remains to be
established. Other backbone modifications may give qualitatively
different responses of use in immunotherapy.
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